STOK - Stoke Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
23.49
-0.20 (-0.84%)
As of 2:06PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close23.69
Open23.92
Bid23.43 x 900
Ask23.54 x 900
Day's Range23.06 - 23.92
52 Week Range19.21 - 1,200.00
Volume50,092
Avg. Volume138,015
Market Cap768.823M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • Behind the Seizure® Program Further Expands Access to Genetic Testing for Children to Speed the Diagnosis of Genetic Epilepsy
    PR Newswire

    Behind the Seizure® Program Further Expands Access to Genetic Testing for Children to Speed the Diagnosis of Genetic Epilepsy

    Today BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) and Invitae Corporation (NYSE: NVTA) announced that Biogen (NASDAQ: BIIB), Encoded Therapeutics, Neurogene, Praxis Precision Medicines and PTC Therapeutics joined Behind the Seizure®, an innovative, cross-company collaboration that aims to provide faster diagnosis for young children with epilepsy. The program will also be expanded to make no-charge testing available for healthcare providers to order for any child under the age of eight who has an unprovoked seizure.

  • Business Wire

    Stoke Therapeutics to Present at 38th Annual J.P. Morgan Healthcare Conference

    Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression, today announced that Chief Executive Officer Edward M. Kaye, M.D., will present at the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2020 at 2:30 p.m. PT (5:30 p.m. ET) in San Francisco.

  • Business Wire

    Stoke Therapeutics Added to NASDAQ Biotechnology Index

    Stoke Therapeutics, Inc. (Nasdaq:STOK), a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq:NBI). This addition is effective prior to market open today.

  • Business Wire

    Stoke Therapeutics Presents Preclinical Data on the Biodistribution, Target Engagement and Safety of STK-001 in Non-Human Primates That Support the Planned Clinical Development of STK-001 for the Treatment of Dravet Syndrome

    Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression, today presented new preclinical data on STK-001, a potential new disease-modifying medicine for the treatment of Dravet syndrome. Data from studies in non-human primates (NHP) showed STK-001 distributed throughout the brain and achieved target engagement and increased Nav1.1 protein expression throughout the cortex after a single intrathecal injection. Safety findings showed STK-001 to be well-tolerated at the two intrathecal dose levels studied. These data were presented today in a poster session at the American Epilepsy Society (AES) Annual Meeting in Baltimore.

  • Business Wire

    Stoke Therapeutics Presents Preclinical Data From Studies of STK-001 That Showed Improvements in Survival and Reductions in Seizure Frequency in a Mouse Model of Dravet Syndrome

    Stoke Therapeutics, Inc. (Nasdaq:STOK), a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression, today announced preclinical data from studies of STK-001 that showed significant improvements in survival and reductions in seizure frequency in a mouse model of Dravet syndrome (DS). New data from electroencephalography (EEG) recordings showed 76% (16/21) of DS mice treated with STK-001 were seizure free compared to 48% (10/21) that were treated with a placebo. An 80% reduction in the average number of spontaneous seizures (3 seizures vs 16 seizures) was also observed among treated DS mice compared to placebo. EEG is a highly sensitive measure of seizure activity, which enables the detection of seizures that may not be otherwise visible. These data were presented in a poster session at the American Epilepsy Society (AES) Annual Meeting in Baltimore.

  • Business Wire

    Stoke Therapeutics to Present at Piper Jaffray 31st Annual Healthcare Conference

    Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression, today announced that Chief Executive Officer Edward M. Kaye, M.D., will present at the Piper Jaffray 31st Annual Healthcare Conference on Wednesday, December 4, 2019 at 11:50 a.m. ET in New York, NY. A live audio webcast of the presentation will be available on the Investors & Media section of Stoke’s website at https://investor.stoketherapeutics.com/.

  • Business Wire

    Stoke Therapeutics to Present New Preclinical Data on STK-001 at the American Epilepsy Society Annual Meeting

    Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression, today announced that it will present new preclinical data on STK-001, a potential new disease-modifying medicine for the treatment of Dravet syndrome, at the American Epilepsy Society (AES) Annual Meeting, taking place December 6-10, 2019 in Baltimore. Data will be presented from preclinical studies demonstrating the effects of STK-001, a proprietary antisense oligonucleotide (ASO), in the Scn1a-linked Dravet syndrome mouse model and in non-human primates. New results of EEG recordings used to measure the frequency of seizures in Dravet syndrome mice treated with STK-001 compared to placebo will be presented, as well as data on STK-001 biodistribution, target engagement, pharmacodynamics, safety and tolerability in non-human primates.

  • Business Wire

    Stoke Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update

    Stoke Therapeutics, Inc., , a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today reported financial results for the third quarter of 2019.

  • Business Wire

    Stoke Therapeutics to Present at Upcoming Investor Conferences in November

    Stoke Therapeutics, Inc. , a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression, today announced that Chief Executive Officer Edward M.

  • Business Wire

    Stoke Therapeutics Strengthens Leadership Team With Appointments of Robin A. Walker, J.D., as Senior Vice President, Chief Legal Officer and Joan Wood as Head of Human Resources

    Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression, today announced the appointments of Robin A. Walker, J.D., as Senior Vice President and Chief Legal Officer, and Joan Wood as Head of Human Resources.

  • Business Wire

    Stoke Therapeutics to Present at 2019 Cantor Global Healthcare Conference

    Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced that Chief Executive Officer Edward M. Kaye, M.D., will present at the 2019 Cantor Global Healthcare Conference on Wednesday, October 2, 2019 at 10:05 a.m. Eastern time in New York, New York. A live audio webcast of the presentation will be available on the Investors & Media section of Stoke’s website at https://investor.stoketherapeutics.com/.

  • Business Wire

    Stoke Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

    Stoke Therapeutics, Inc. , a biotechnology company that is pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced the closing of its initial public offering of 9,074,776 shares of its common stock at a price to the public of $18.00 per share, which includes 1,183,666 shares sold upon full exercise of the underwriters’ option ...

  • Business Wire

    Stoke Therapeutics Announces Pricing of Initial Public Offering

    Stoke Therapeutics, Inc., a biotechnology company that is pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced the pricing of its initial public offering of 7,891,110 shares of its common stock at a price to the public of $18.00 per share. All of the shares are being offered by Stoke. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Stoke, are expected to be approximately $142.0 million.